Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Sarcoma 1Other neoplasm 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Precancerous Conditions 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Keratosis, Actinic 1Dermatitis, Contact 1Carcinoma, Basal Cell 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Triamcinolone × Dermatologic × Clear all
NCT03380026 2021-11-24

MIDAS

Rochester Skin Lymphoma Medical Group, PLLC

Phase 2 Completed
28 enrolled 8 charts
DermatologicLymphoid

Dermatitis, Contact, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT00021294 2018-09-11

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

University of Arizona

Phase 2 Completed
DermatologicOther neoplasm

Carcinoma, Basal Cell, Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡